Citations

Showing 10 of 108083 citations.

Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines
Karlic, Heidrun , Haider, Florian, Thaler, Roman, Spitzer, Silvia , Klaushofer, Klaus, Varga, Franz

Mayo Clinic

International Journal of Molecular Sciences | September 15, 2017 | Volume: 18 | Issue: 9 | Pages: 1982

10.3390/ijms18091982 | PMID 28914765 Get It

Statins and bisphosphonates are increasingly recognized as anti-cancer drugs, especially because of their cholesterol-lowering properties. However, these drugs act differently on various types of cancers. Thus, the aim of this study was to compare the effects of statins and bisphosphonates on the metabolism (NADP+/NADPH-relation) of highly proliferative tumor cell lines from different origins (PC-3 prostate carcinoma, MDA-MB-231 breast cancer, U-2 OS osteosarcoma) versus cells with a slower proliferation rate like MG-63 osteosarcoma cells. Global gene expression analysis revealed that after 6 days of treatment with pharmacologic doses of the statin simvastatin and of the bisphosphonate ibandronate, simvastatin regulated more than twice as many genes as ibandronate, including many genes associated with cell cycle progression. Upregulation of starvation-markers and a reduction of metabolism and associated NADPH production, an increase in autophagy, and a concomitant downregulation of H3K27 methylation was most significant in the fast-growing cancer cell lines. This study provides possible explanations for clinical observations indicating a higher sensitivity of rapidly proliferating tumors to statins and bisphosphonates.
Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry
Bonnot, Olivier , Gama, Clarissa Severino , Mengel, Eugen , Pineda, Mercè , Vanier, Marie T. , Watson, L. , Watissée, Marie, Schwierin, Barbara, Patterson, Marc C.

Mayo Clinic

The World Journal of Biological Psychiatry | September 15, 2017 | Volume: 20 | Issue: 4 | Pages: 310-319

10.1080/15622975.2017.1379610 | PMID 28914127 Get It

Anatomical features of the cervical spinal canal in Chiari I deformity with presyrinx: A case-control study
Gadde, Judith A. , Pomeraniec, I. Jonathan , Bakke, S. J., Frič, Radek , Ksendzovsky, Alexander , Jane, John A. , Schwartz, Erin Simon , Haughton, Victor M. , Liebo, Greta B. , Shah, Vinil N. , Ringstad, Geir André

Mayo Clinic

The Neuroradiology Journal | September 15, 2017 | Volume: 30 | Issue: 5 | Pages: 405-409

10.1177/1971400917718842 | PMID 28691569 Get It

Purpose The relationship between syringomyelia and presyrinx, characterized by edema in the spinal cord, has not been firmly established. Patients with syringomyelia have abnormal spinal canal tapering that alters cerebrospinal fluid flow dynamics, but taper ratios in presyrinx have never been reported. We tested the hypothesis that presyrinx patients have abnormal spinal canal tapering. Materials and methods At six medical institutions, investigators searched the PACS system for patients with Chiari I and spinal cord edema unassociated with tumor, trauma, or other evident cause. In each case taper ratios were calculated for C1 to C4 and C4 to C7. In two age- and gender-matched control groups, Chiari I patients with no syringomyelia and patients with normal MR scans, the same measurements were made. Differences between groups were tested for statistical significance with t tests. Results The study enrolled 21 presyrinx patients and equal numbers of matched Chiari I and normal controls. C4 to C7 taper ratios were positive and steeper in presyrinx patients than in the normal controls ( p = 0.04). The upper cervical spine, C1 to C4, tapered negatively in cases and controls without significant differences between the groups. The difference in degree of tonsillar herniation was statistically significant between presyrinx patients and Chiari I controls ( p = 0.01). Conclusions Presyrinx patients have greater than normal positive tapering in the lower cervical spine and greater degree of tonsillar herniation than the controls.
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma
Davila, Jaime , Starr, Jason S. , Attia, Steven , Knudson, Ryan A., Necela, Brian M. , Sarangi, Vivekananda , Sun, Zhifu , Ren, Yingxue , Casler, John D., Menke, David M. , Oliver, Gavin R. , Copland, John A. , Parker, Alexander S. , Kocher, Jean-Pierre A., Thompson, E. Aubrey , Smallridge, Robert C., Asmann, Yan W. , Davila, Jaime I, Sun, Zhifu , Davila, Jaime I , Wang, Chen , Joseph, Richard W.

Mayo Clinic

Rare Tumors | September 15, 2017 | Volume: 9 | Issue: 2 | Pages: 50-53

10.4081/rt.2017.6834 | PMID 28975018 Get It

We previously reported an extremely rare case of follicular dendritic cell sarcoma (FDCS) presented as a thyroid mass. Given the rarity of this disease, there are no personalized and molecularly targeted treatment options due to the lack of knowledge in the genomic makeup of the tumor. A 44-year-old white woman was diagnosed with an extranodal FDCS in thyroid. The patient underwent a total thyroidectomy, central compartment dissection, parathyroid re-implantation, and adjuvant radiation therapy. Tumor DNA sequencing of 236 genes by FoundationOne panel found truncating mutations in PTEN and missense mutations in RET and TP53. However, patient-matched germline DNA was not sequenced which is critical for identification of true somatic mutations. Furthermore, the FoundationOne panel doesn't measure genomic rearrangements which have been shown to be abundant in sarcomas and are associated with sarcoma tumorigenesis and progression. In the current study, we carried out comprehensive genomic sequencing of the tumor, adjacent normal tissues, and patient-matched blood, in an effort to understand the genomic makeup of this rare extranodal FDCS and to identify potential therapeutic targets. Eighty-one somatic point mutations were identified in tumor but not in adjacent normal tissues or blood. A clonal truncating mutation in the CLTCL1 gene, which stabilizes the mitotic spindle, was likely a driver mutation of tumorigenesis and could explain the extensive copy number aberrations (CNAs) and genomic rearrangements in the tumor including a chr15/chr17 local chromothripsis resulted in 6 expressed fusion genes. The fusion gene HDGFRP3→SHC4 led to a 200-fold increase in the expression of oncogene SHC4 which is a potential target of the commercial drug Dasatinib. Missense mutations in ATM and splice-site mutation in VEGFR1 were also detected in addition to the TP53 missense mutation reported by FoundationOne.
Relationship of Number of Missing Teeth to Hip Fracture in Elderly Patients: A Cohort Pilot Study
Priebe, Jennifer, Wermers, Robert A. , Sems, S.A. , Viozzi, Christopher F. , Koka, Sreenivas , Sems, Stephen A

Mayo Clinic

Journal of Prosthodontics | September 15, 2017 | Volume: 28 | Issue: 3 | Pages: 258-263

10.1111/jopr.12626 | PMID 28913949 Get It

AbstractPurposeTo determine the relationship between the number of missing natural teeth or remaining natural teeth and osteoporotic hip fracture in elderly patients and to determine the relationship between the number of missing teeth or remaining teeth and osteoporotic fracture risk assessment (FRAX) probability.Materials and MethodsNumber of missing teeth was determined by clinical oral exam on a total of 100 subjects, 50 with hip fractures and 50 without. Ten‐year fracture risk and hip fracture risk probabilities were calculated using the FRAX tool. Statistical analyses were performed to determine strength of associations between number of missing natural teeth and likelihood of experiencing a fracture. Degree of correlation between number of missing natural teeth and FRAX probabilities were calculated.ResultsThere appears to be an association between the number of missing natural teeth and hip fractures. For every 5‐tooth increase in the number of missing teeth, the likelihood of being a subject in the hip fracture group increased by 26%. Number of missing natural teeth was positively correlated with FRAX overall fracture and hip fracture probability.ConclusionsNumber of missing natural teeth may be a valuable tool to assist members of medical and dental teams in identifying patients with higher FRAX scores and higher likelihood of experiencing a hip fracture. Additional research is necessary to validate these findings.
Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival
Müller-Greven, Gaëlle, Carlin, Cathleen R. , Burgett, Monica E., Ahluwalia, Manmeet S. , Nowacki, Amy S. , Herting, Cameron J. , Qadan, Maha A. , Bredel, Markus , Lathia, Justin D. , Hamerlik, Petra , Gladson, Candece L. , Lauko, Adam J. , Toms, Steven A. , Hambardzumyan, Dolores , Sarkaria, Jann N. , Ahluwalia, Manmeet S , Hamerlik, Petra

Mayo Clinic

Clinical Cancer Research | September 14, 2017 | Volume: 23 | Issue: 22 | Pages: 7059-7071

10.1158/1078-0432.ccr-17-0249 | PMID 28912141 Get It

Abstract Purpose: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space in tumors. Experimental Design: Established orthotopic xenograft and syngeneic models of GBM were used to determine entry of monoclonal anti-VEGF-A into, and uptake by cells in, the perivascular space. Based on the results, we examined CD133+ cells derived from GBM tumors in vitro. Bevacizumab internalization, trafficking, and effects on cell survival were analyzed using multilabel confocal microscopy, immunoblotting, and cytotoxicity assays in the presence/absence of inhibitors. Results: In the GBM mouse models, administered anti-mouse-VEGF-A entered the perivascular tumor niche and was internalized by Sox2+/CD44+ tumor cells. In the perivascular tumor cells, bevacizumab was detected in the recycling compartment or the lysosomes, and increased autophagy was found. Bevacizumab was internalized rapidly by CD133+/Sox2+-GBM cells in vitro through macropinocytosis with a fraction being trafficked to a recycling compartment, independent of FcRn, and a fraction to lysosomes. Bevacizumab treatment of CD133+ GBM cells depleted VEGF-A and induced autophagy thereby improving cell survival. An inhibitor of lysosomal acidification decreased bevacizumab-induced autophagy and increased cell death. Inhibition of macropinocytosis increased cell death, suggesting macropinocytosis of bevacizumab promotes CD133+ cell survival. Conclusions: We demonstrate that bevacizumab is internalized by Sox2+/CD44+-GBM tumor cells residing in the perivascular tumor niche. Macropinocytosis of bevacizumab and trafficking to the lysosomes promotes CD133+ cell survival, as does the autophagy induced by bevacizumab depletion of VEGF-A. Clin Cancer Res; 23(22); 7059–71. ©2017 AACR.
Hypertrophic Obstructive Cardiomyopathy
Seggewiß, Hubert , Schaff, Hartzell V. , Seggewiss, Hubert, Schaff, Hartzell , Nishimura, Rick A.

Mayo Clinic

Circulation Research | September 14, 2017 | Volume: 121 | Issue: 7 | Pages: 771-783

10.1161/circresaha.116.309348 | PMID 28912182 Get It

Hypertrophic cardiomyopathy is a genetic disorder characterized by marked hypertrophy of the myocardium. It is frequently accompanied by dynamic left ventricular outflow tract obstruction and symptoms of dyspnea, angina, and syncope. The initial therapy for symptomatic patients with obstruction is medical therapy with β-blockers and calcium antagonists. However, there remain a subset of patients who have continued severe symptoms, which are unresponsive to medical therapy. These patients can be treated with septal reduction therapy, either surgical septal myectomy or alcohol septal ablation. When performed by experienced operators working in high-volume centers, septal myectomy is highly effective with a >90% relief of obstruction and improvement in symptoms. The perioperative mortality rate for isolated septal myectomy in most centers is <1%. Alcohol septal ablation is a less invasive treatment. In many patients, the hemodynamic and clinical results are comparable to that of septal myectomy. However, the results of alcohol septal ablation are dependent on the septal perforator artery supplying the area of the contact between the hypertrophied septum and the anterior leaflet of the mitral valve. There are some patients, particularly younger patients with severe hypertrophy, who do not uniformly experience complete relief of obstruction and symptoms. Both techniques of septal reduction therapy are highly operator dependent. The final decision as to which approach should be selected in any given patient is dependent up patient preference and the availability and experience of the operator and institution at which the patient is being treated.
Trans‐nasal flexible bronchoscopy in wheezing children: Diagnostic yield, impact on therapy, and prevalence of laryngeal cleft
Boesch, R. Paul , Baughn, Julie , Cofer, Shelagh A. , Balakrishnan, Karthik , Boesch, Richard P , Baughn, Julie M, Balakrishnan, Karthik

Mayo Clinic

Pediatric Pulmonology | September 14, 2017 | Volume: 53 | Issue: 3 | Pages: 310-315

10.1002/ppul.23829 | PMID 28910519 Get It

AbstractAimPersistent or recurrent wheezing is a common indication for flexible bronchoscopy, as anatomic and infectious or inflammatory changes are highly prevalent. We sought to evaluate the prevalence of anatomic, infectious, and inflammatory disease in a cohort of children undergoing flexible bronchoscopy for wheezing or poorly controlled asthma.MethodsWe retrospectively reviewed all children <18 years old who underwent flexible bronchoscopy at our center from October 29, 2012‐December 31, 2016 for the primary or secondary indication of wheezing (persistent, frequently recurring, or atypical) or poorly controlled asthma.ResultsA total of 101 procedures were identified in 94 patients, aged 3 months to 18 years. Potential anatomic causes for wheezing identified in 45.7% of patients and inflammatory changes in 49.5% of procedures. This included the identification of a laryngeal cleft in 17% for which half required medical or surgical management. Tracheobronchomalacia was the most commonly identified anatomic lesion. Thirty children from this cohort had poorly controlled asthma. Among this subgroup, 54% had increased neutrophils on BAL and 30% had an anatomic contributor to wheezing, including one with a laryngeal cleft. Based on findings from flexible bronchoscopy, management changes made in 63.8% of patients. This included medication changes in 54 and surgical intervention in 9.DiscussionWe conclude that transnasal flexible bronchoscopy has high yield in children with recurrent, persistent, or atypical wheezing and those with poorly controlled asthma. Laryngeal cleft has a reasonably high prevalence that warrants specific evaluation in this population.
Restrictive Cardiomyopathy
Muchtar, Eli , Blauwet, Lori A., Muchtar, E , Gertz, Morie A.

Mayo Clinic

Circulation Research | September 14, 2017 | Volume: 121 | Issue: 7 | Pages: 819-837

10.1161/circresaha.117.310982 | PMID 28912185 Get It

Restrictive cardiomyopathy (RCM) is characterized by nondilated left or right ventricle with diastolic dysfunction. The restrictive cardiomyopathies are a heterogenous group of myocardial diseases that vary according to pathogenesis, clinical presentation, diagnostic evaluation and criteria, treatment, and prognosis. In this review, an overview of RCMs will be presented followed by a detailed discussion on 3 major causes of RCM, for which tailored interventions are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis. Each of these 3 RCMs is challenging to diagnose, and recognition of each disease entity is frequently delayed. Clinical clues to promote recognition of cardiac amyloidosis, cardiac sarcoidosis, and cardiac hemochromatosis and imaging techniques used to facilitate diagnosis are discussed. Disease-specific therapies are reviewed. Early recognition remains a key barrier to improving survival in all RCMs.
Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia
Wang, Huan‐You , Feldman, Andrew L. , Feldman, Andrew L

Mayo Clinic

Blood | September 14, 2017 | Volume: 130 | Issue: 11 | Pages: 1387-1387

10.1182/blood-2017-04-779017 | PMID 28912296 Get It